Dermira revealed plans for a $75m initial public offering on 27 August, just one week after the company closed a $51m Series C venture capital funding round.
Before the Series C, Redwood City, California-based Dermira had just $9.8m in cash as of 30 June. The company said...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
